Partners Tim Powell and Vishnu Shankar and associate Ben Rowlatt authored an article in Life Sciences Intellectual Property Review discussing how artificial intelligence is rapidly changing the pharmaceutical and biotech industries, particularly in areas such as drug discovery, personalized medicine, and pharmacovigilance. They also highlight the challenges AI poses for current patent laws and applicable data protection regulations.
Read the full Life Sciences Intellectual Property Review article >>